BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32423277)

  • 21. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
    Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
    Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lung Deposition and Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease Using Different Inhalation Devices: A Systematic Literature Review and Expert Opinion.
    Baloira A; Abad A; Fuster A; García Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL; González-Torralba F
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1021-1033. PubMed ID: 33907390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usage and usability of one dry powder inhaler compared to other inhalers at therapy start: an open, non-interventional observational study in Poland and Germany.
    Hantulik P; Wittig K; Henschel Y; Ochse J; Vahteristo M; Rytila P
    Pneumonol Alergol Pol; 2015; 83(5):365-77. PubMed ID: 26378998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lung characteristics in elderly males and females patients with COPD: differences and optimal use of dry powder inhalers (DPIs).
    Terzano C; Oriolo F
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2708-2716. PubMed ID: 28678314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nebulized Therapies in COPD: Past, Present, and the Future.
    Barjaktarevic IZ; Milstone AP
    Int J Chron Obstruct Pulmon Dis; 2020; 15():1665-1677. PubMed ID: 32764912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers.
    Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Nabil Salem M; Rabea H; Abdelrahim MEA
    Exp Lung Res; 2018; 44(4-5):211-216. PubMed ID: 30346848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
    Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
    Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
    J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The dry powder inhaler features of the Easyhaler that benefit the management of patients.
    Chrystyn H; Lavorini F
    Expert Rev Respir Med; 2020 Apr; 14(4):345-351. PubMed ID: 32013627
    [No Abstract]   [Full Text] [Related]  

  • 30. Performance of Turbuhaler((R)) in Patients with Acute Airway Obstruction and COPD, and in Children with Asthma : Understanding the Clinical Importance of Adequate Peak Inspiratory Flow, High Lung Deposition, and Low In Vivo Dose Variability.
    Selroos O; Borgström L; Ingelf J
    Treat Respir Med; 2006; 5(5):305-15. PubMed ID: 16928144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of use of dry powder inhalers versus pressurized metered-dose inhalers devices in adult patients with chronic obstructive pulmonary disease or asthma: An observational comparative study.
    Ramadan WH; Sarkis AT
    Chron Respir Dis; 2017 Aug; 14(3):309-320. PubMed ID: 28774201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of an external resistance to airflow on the inspiratory flow curve.
    de Koning JP; van der Mark TW; Coenegracht PM; Tromp TF; Frijlink HW
    Int J Pharm; 2002 Mar; 234(1-2):257-66. PubMed ID: 11839456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults.
    Melani AS; Zanchetta D; Barbato N; Sestini P; Cinti C; Canessa PA; Aiolfi S; Neri M;
    Ann Allergy Asthma Immunol; 2004 Nov; 93(5):439-46. PubMed ID: 15562882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Measurement of inspiratory flow for the selection of the inhalation treatment device for asthma and COPD].
    Plavec D; Gluncić TJ; Gudelj I; Mise K
    Lijec Vjesn; 2012; 134(3-4):84-9. PubMed ID: 22768682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
    Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
    Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of inspiratory flow in selection and use of inhaled therapy for patients with chronic obstructive pulmonary disease.
    Mahler DA
    Respir Med; 2020 Jan; 161():105857. PubMed ID: 32056720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised open-label cross-over study of inhaler errors, preference and time to achieve correct inhaler use in patients with COPD or asthma: comparison of ELLIPTA with other inhaler devices.
    van der Palen J; Thomas M; Chrystyn H; Sharma RK; van der Valk PD; Goosens M; Wilkinson T; Stonham C; Chauhan AJ; Imber V; Zhu CQ; Svedsater H; Barnes NC
    NPJ Prim Care Respir Med; 2016 Nov; 26():16079. PubMed ID: 27883002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing inhalation therapy in the aspect of peak inhalation flow rate in patients with chronic obstructive pulmonary disease or asthma.
    Hua JL; Ye XF; Du CL; Xie N; Zhang JQ; Li M; Zhang J
    BMC Pulm Med; 2021 Sep; 21(1):302. PubMed ID: 34560863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease.
    Burnell PK; Small T; Doig S; Johal B; Jenkins R; Gibson GJ
    Respir Med; 2001 May; 95(5):324-30. PubMed ID: 11392571
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler.
    Sorino C; Negri S; Spanevello A; Visca D; Scichilone N
    Eur J Intern Med; 2020 May; 75():15-18. PubMed ID: 32113944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.